Compare AU
Compare ETPMAG vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are ETPMAG and DRUG. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.
Community Stats
ETPMAG | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 84 | 61 |
Median incremental investment | $5,064.50 | $920.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $4,712.26 | $1,976.53 |
Average age group | > 35 | 26 - 35 |
Key Summary
ETPMAG | DRUG | |
|---|---|---|
Strategy | ETPMAG.AX was created on 2009-01-02 by Global X. The fund's investment portfolio concentrates primarily on silver commodities. ETFS Physical Silver (ETPMAG.AX) is designed to offer investors a simple, costefficient and secure way to access physical silver by providing a return equivalent to the movements in the silver spot price less the applicable management fee. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | Global X Metal Securities Australia Limited (100 %) | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) |
Top 3 industries | Other (75.92 %) Communication Services (33.53 %) Health Care (23.94 %) | |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | |
Management fee | 0.49 % | 0.57 % |
Key Summary
ETPMAG | DRUG | |
|---|---|---|
Issuer | Global X | BetaShares |
Tracking index | LBMA Silver Spot Price AUD | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.49 % | 0.57 % |
Price | $48.58 | $8.27 |
Size | $450.866 million | $195.730 million |
10Y return | 146.22 % | N/A |
Annual dividend/ distribution yield (5Y) | - % | 1.89 % |
Market | ASX | ASX |
First listed date | 30/01/2009 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
ETPMAG | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 84 | 61 |
Median incremental investment | $5,064.50 | $920.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $4,712.26 | $1,976.53 |
Average age group | > 35 | 26 - 35 |
Pros and Cons
ETPMAG | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
ETPMAG | DRUG |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |